Search results
Results from the WOW.Com Content Network
Essential thrombocythemia is sometimes described as a slowly progressive disorder with long asymptomatic periods punctuated by thrombotic or hemorrhagic events. [15] However, well-documented medical regimens can reduce and control the number of platelets, which reduces the risk of these thrombotic or hemorrhagic events.
The SARS disease caused thrombocytosis. [10] Once the reactive causes of thrombocythemia are ruled out, clonal thrombocythemia should be considered. The most common cause of clonal thrombocythemia is a myeloproliferative neoplasm. These include: essential thrombocythemia, chronic myelogenous leukemia, polycythemia vera, and primary ...
Anagrelide is used to treat essential thrombocytosis, especially when the current treatment of the patient is insufficient. [4] Essential thrombocytosis patients who are suitable for anagrelide often meet one or more of the following factors: [5] [6] age over 60 years; platelet count over 1000×10 9 /L; a history of thrombosis
Hydroxycarbamide, also known as hydroxyurea, is an antimetabolite medication used in sickle-cell disease, essential thrombocythemia, chronic myelogenous leukemia, polycythemia vera, and cervical cancer. [4] [5] In sickle-cell disease it increases fetal hemoglobin and decreases the number of attacks. [4] It is taken by mouth. [4]
Plateletpheresis (more accurately called thrombocytapheresis or thrombapheresis, though these names are rarely used) is the process of collecting thrombocytes, more commonly called platelets, a component of blood involved in blood clotting.
Similarly, myeloproliferative disorders, in which the bone marrow produces too many blood cells, predispose to thrombosis, particularly in polycythemia vera (excess red blood cells) and essential thrombocytosis (excess platelets). Again, these conditions usually warrant specific treatment when identified. [21]
A 2006 follow-up of 553 patients using imatinib (Gleevec) found an overall survival rate of 89% after five years. [33] A 2011 followup of 832 patients using imatinib who achieved a stable cytogenetic response found an overall survival rate of 95.2% after 8 years, which is similar to the rate in the general population.
José Salvador Alvarenga (Spanish: [xoˈse salβaˈðoɾ alβaˈɾeŋɡa]; born c. 1975) is a Salvadoran fisherman and author who was found on January 30, 2014, aged 36 or 37, [nb 1] on the Marshall Islands after spending 14 months adrift in a fishing boat in the Pacific Ocean beginning on November 17, 2012.